- Home
- ADPT vs JFR Comparison
ADPT vs JFR Comparison
Compare ADPT & JFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- JFR
- Stock Information
- Founded
- ADPT 2009
- JFR 2004
- Country
- ADPT United States
- JFR United States
- Employees
- ADPT N/A
- JFR N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- JFR Trusts Except Educational Religious and Charitable
- Sector
- ADPT Health Care
- JFR Finance
- Exchange
- ADPT Nasdaq
- JFR Nasdaq
- Market Cap
- ADPT 1.1B
- JFR 1.1B
- IPO Year
- ADPT 2019
- JFR N/A
- Fundamental
- Price
- ADPT $7.43
- JFR $8.50
- Analyst Decision
- ADPT Strong Buy
- JFR
- Analyst Count
- ADPT 5
- JFR 0
- Target Price
- ADPT $9.40
- JFR N/A
- AVG Volume (30 Days)
- ADPT 2.2M
- JFR 621.7K
- Earning Date
- ADPT 05-06-2025
- JFR 01-01-0001
- Dividend Yield
- ADPT N/A
- JFR 11.31%
- EPS Growth
- ADPT N/A
- JFR N/A
- EPS
- ADPT N/A
- JFR N/A
- Revenue
- ADPT $178,957,000.00
- JFR N/A
- Revenue This Year
- ADPT $21.21
- JFR N/A
- Revenue Next Year
- ADPT $21.98
- JFR N/A
- P/E Ratio
- ADPT N/A
- JFR N/A
- Revenue Growth
- ADPT 5.10
- JFR N/A
- 52 Week Low
- ADPT $2.28
- JFR $7.61
- 52 Week High
- ADPT $9.01
- JFR $8.82
- Technical
- Relative Strength Index (RSI)
- ADPT 44.19
- JFR 48.67
- Support Level
- ADPT $6.92
- JFR $8.36
- Resistance Level
- ADPT $9.01
- JFR $8.47
- Average True Range (ATR)
- ADPT 0.57
- JFR 0.06
- MACD
- ADPT -0.01
- JFR 0.01
- Stochastic Oscillator
- ADPT 24.58
- JFR 64.71
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income, consistent with the preservation of capital. It invests in adjustable-rate U.S. dollar-denominated secured Senior Loans.